Clinical trials: Survival Outcomes
ALK-positive NSCLC
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
This study aims to explore for the first time how the different ALK TKIs have been sequenced in real-world clinical practice and with which outcomes for Swedish lung cancer patients
- Trial name
- NCT04647110
- Testing
- crizotinib, alectinib, brigatinib
- Where
- Sweden
- Volunteers
- 549 people
- Sponsor
- Pfizer
Prostatic Neoplasms, Castration-Resistant
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05968599
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 2,731 people
- Sponsor
- Pfizer
Heart Failure, Anemia
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in…
- Conditions
- Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction
- Trial name
- NCT00358215
- Testing
- Darbepoetin alfa
- Where
- 754 sites in United States, Argentina and 34 more
- Volunteers
- 2,278 people
- Sponsor
- Amgen
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
- Trial name
- NCT01313676
- Testing
- fluticasone furoate/vilanterol, fluticasone furoate, vilanterol
- Where
- 1,611 sites in United States, Argentina and 42 more
- Volunteers
- 16,568 people
- Sponsor
- GlaxoSmithKline
Prostatic Neoplasms, Castration-Resistant
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone…
- Trial name
- NCT05520138
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 5,506 people
- Sponsor
- Pfizer